Zymeworks Inc.
ZYME evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZYME—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZYME
Zymeworks Inc. is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diversified pipeline of novel, multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, with a strategy focused on royalty growth, strategic acquisitions, and internal innovation.
Key risk: Continued net losses
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 3 clinical trials for Zymeworks Inc..
Zymeworks Inc. is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diversified pipeline of novel, multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, with a strategy focused on royalty growth, strategic acquisitions, and internal innovation.
- As of June 30, 2026, Zymeworks reported cash & equivalents of $179.4M, total revenue of $4.6M, and a net loss of -$45.0M [sec].
- The company has an accumulated deficit of $953.2M as of December 31, 2025, and expects to continue incurring operating losses in the near to medium term [sec_mda · as of 2026-03-02].
- Zymeworks' strategy emphasizes royalty growth, strategic acquisitions, and disciplined capital allocation, supported by expected milestone payments and royalties from existing commercial partners [sec_mda · as of 2026-08-06].
- The pipeline includes multispecific antibody therapeutics (MSATs) and antibody-drug conjugates (ADCs) targeting cancer, inflammation, and autoimmune diseases [sec_mda · as of 2026-05-07].
- Zymeworks is advancing Phase 1 clinical studies for ZW191 and ZW251 during 2026, and plans to continue preclinical and clinical development of other ADC programs [sec_mda · as of 2026-05-07].
What works
- Zymeworks has a diversified portfolio strategy that includes royalty revenue from partnered products like zanidatamab (via Jazz and BeOne), providing a potential source of recurring cash flows [sec_mda · as of 2025-11-06].
- The company leverages proprietary technology platforms (MSATs and ADCs) and a structure-guided molecular modeling engine to develop next-generation biotherapeutics for hard-to-treat diseases [sec_mda · as of 2026-05-07].
- Strategic partnerships and risk-sharing collaborations reduce reliance on internal capital for late-stage development and support disciplined R&D investment [sec_mda · as of 2026-08-06].
- As of September 30, 2025, Zymeworks had $299.4M in cash resources and anticipated funding for at least twelve months from that date, indicating a near-term liquidity runway [sec_mda · as of 2025-11-06].
What to weigh
- Zymeworks has a history of net losses, reporting a net loss of $81.1M for 2025 and an accumulated deficit of $953.2M as of December 31, 2025, with expectations of continued losses in the near to medium term [sec_mda · as of 2026-03-02].
- The company has not generated revenue from any wholly-owned product candidates and does not expect to do so until regulatory approval and commercialization, which is uncertain [sec_mda · as of 2025-11-06].
- Cash resources decreased from $299.4M as of September 30, 2025 to $179.4M as of June 30, 2026, reflecting ongoing cash burn from R&D and operations [sec].
- Inflationary pressures and the inherent risks of drug development could adversely impact financial results and funding requirements [sec_mda · as of 2026-05-07].
From the filings
Quoted directly from source documents.
Zymeworks reported a net loss of $81.1 million for 2025 and an accumulated deficit of $953.2 million.
“We reported a net loss of $81.1 million for the year ended December 31, 2025, and through December 31, 2025, we had an accumulated deficit of $953.2 million.”
SEC MD&A · March 2, 2026
Zymeworks' strategy focuses on royalty growth, strategic acquisitions, and internal innovation.
“Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners.”
SEC MD&A · August 6, 2026
Zymeworks is advancing Phase 1 studies for ZW191 and ZW251 in 2026.
“With respect to our ADC portfolio, we currently expect to continue conducting Phase 1 clinical studies for ZW191 and ZW251 during 2026.”
SEC MD&A · May 7, 2026
Zymeworks had $299.4 million in cash resources as of September 30, 2025.
“As of September 30, 2025, we had $299.4 million of cash resources consisting of cash, cash equivalents and marketable securities.”
SEC MD&A · November 6, 2025
Risks & what to watch (4)›
Key risks
- Continued net losses — Zymeworks reported a net loss of $81.1M for 2025 and expects ongoing losses, with an accumulated deficit of $953.2M [sec_mda · as of 2026-03-02].
- No revenue from own products — The company has not generated revenue from any wholly-owned product candidates and may never do so [sec_mda · as of 2025-11-06].
- Cash burn and decreasing reserves — Cash decreased from $299.4M (Sep 2025) to $179.4M (Jun 2026), indicating significant cash burn [sec].
- Inflationary and development risks — Inflationary pressure and inherent drug development risks could adversely impact financial results [sec_mda · as of 2026-05-07].
What to watch
- Progress of Phase 1 clinical studies for ZW191 and ZW251 during 2026 [sec_mda · as of 2026-05-07].
- Receipt of milestone payments and royalty revenue from partners like Jazz and BeOne [sec_mda · as of 2025-11-06].
- Execution of the asset and royalty aggregation strategy, including potential strategic acquisitions [sec_mda · as of 2026-08-06].
- Updates on the ADVANCE research efforts focused on multispecific antibody and engineered-cytokine platforms [sec_mda · as of 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Zymeworks Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zymeworks Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
20.2 months
D/E 3.94 · 0% dilution
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
212
Total value held
$1.14B
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 7,020,156 | $175.8M |
| blackrock, inc. | 4,553,888 | $114.0M |
| bvf inc/il | 3,734,142 | $93.5M |
| vanguard capital management llc | 3,411,160 | $85.4M |
| morgan stanley | 2,480,568 | $62.1M |
| bnp paribas asset management holding s.a. | 1,908,039 | $47.8M |
| citadel advisors llc | 1,250,518 | $31.3M |
| dimensional fund advisors lp | 1,139,135 | $28.5M |
| nextech invest, ltd. | 1,113,946 | $27.9M |
| state street corp | 1,011,777 | $25.3M |
Showing top 10 of 212 institutional holders of Zymeworks Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 9.4%
- Days to cover
- 7.6
- Shares short
- 4,648,225
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZYME short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zymeworks Inc.?
Zymeworks Inc. is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diversified pipeline of novel, multifunctional biotherapeutics for cancer, inflammation, and autoimmune diseases, with a strategy focused on royalty growth, strategic acquisitions, and internal innovation.
What is Zymeworks Inc.'s lead drug candidate?
Zymeworks Inc.'s most advanced tracked candidate is ziihera (Approved) for previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC).
Who is the CEO of Zymeworks Inc.?
Mr. Kenneth H. Galbraith C.A. is the chief executive officer of Zymeworks Inc. (ZYME).
Where is Zymeworks Inc. headquartered?
Zymeworks Inc. (ZYME) is headquartered in Middletown, DE, United States.
What therapeutic areas does Zymeworks Inc. focus on?
Zymeworks Inc. develops therapies across Oncology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.